Princeton BioPharma Capital Partners, LLC #generic #pharmaceuticals #companies


Posted On Aug 11 2017 by

#aton pharma

#

Michael Wells

Michael is a Managing Director at Princeton Biopharma Capital Partners, LLC a boutique private equity firm focused on providing growth capital and operating expertise to commercial stage healthcare companies. He is a veteran of the pharmaceutical industry with extensive expertise in licensing and commercialization of prescription pharmaceuticals around the world. Prior to forming Princeton Biopharma Capital, LLC, he was the founder and CEO of Aton Pharma, Inc. a specialty pharmaceutical company with products that treated orphan diseases. Michael started the company in 2004 with a blank piece of paper and a dream. By 2010, the company was on track to surpass $100 million in revenue and $35 million of EBITDA with 11 products sold in over 30 countries. In 2010 the company was sold to Valeant Pharmaceuticals International for $330 million. In 2009 Michael was a winner of the Ernst Young Entrepreneur of the Year Award.

Prior to forming Aton, Michael co-founded Lathian Systems Inc. a venture-backed company that provides online data and marketing services to pharmaceutical and biotech companies. At Lathian, he held several senior management positions, including Vice President of Marketing, Vice President of Sales, Vice President of Operations and Director. His career began at Merck Co. Inc. where he held positions ranging from hospital sales to brand management. He holds a BS and MS from the University of Pittsburgh and an MBA from The Wharton School.

George Parise

George is a Managing Director at Princeton Biopharma Capital Partners, LLC with strong experience in the pharmaceutical industry and in private equity. Prior to co-founding Princeton Biopharma Capital Partners, LLC, George was the Chief Financial Officer of Aton Pharma, Inc. a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. George provided financial leadership to Aton through two acquisitions, a $30MM credit facility entered into in the difficult credit environment of 2009, and the sale of Aton to Valeant Pharmaceuticals in the Spring of 2010.

Prior to joining Aton, George was an operating executive with Cerberus Operations and Advisory Company, leading diligence efforts and assuming key operating roles within portfolio companies. During his tenure with Cerberus, George’s positions included Chief Financial Officer of Velocita Wireless, where he led the complex standalone transition of this Cingular Wireless carve-out and spearheaded the eventual successful sale to Sprint. Prior to his time at Cerberus, Mr. Parise was the Senior VP of Finance for CAI Wireless Systems, a publicly held wireless telecommunication services provider, where he offered financial leadership to the organization through several business plan changes, a financial restructuring through Chapter 11 of the US Bankruptcy Code, and the successful sale of the company. Prior to CAI, Mr. Parise was the Chief Financial Officer of CellularVision, a pioneer in the development of wireless telecommunication services, where he led the company’s successful initial public stock offering. Mr. Parise has also held the position of Staff Vice President of Accounting at TriCon Leasing Corporation (a former subsidiary of Verizon), and has held several progressing positions with Ernst Young. Mr. Parise holds a BS in Accounting from Seton Hall University and is a CPA (inactive).

Barry Levinson

Barry is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Barry was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Barry was a founding employee of Aton Pharma, Inc. a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Barry identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton’s products to new medical uses, and spearheaded programs to develop these new indications.

Before Aton, Barry was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Dr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering’s Office of Technology. Before Berlex, Dr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company’s Radiation Safety Officer. Dr. Levinson received his PhD and Master’s degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.

2016 Princeton Biopharma Capital Partners, LLC





Last Updated on: August 11th, 2017 at 8:58 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *